Evidence map›Paper›PMID 42642072›Full record

ArticleHealth services research2026

Medicare Advantage Plan Bid Risk Underestimates and Corresponding Insurer Revenues.

David Scheinker, Kevin Schulman, Barak Richman, Arnold Milstein, Richard Kronick

Abstract read
In one paragraph

Article in Health services research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

David ScheinkerDepartment of Pediatrics, Stanford Medical School, Stanford University, Palo Alto, California, USA.ORCID https://orcid.org/0000-0001-5885-8024
Kevin SchulmanDepartment of Medicine, Stanford Medical School, Stanford University, Palo Alto, California, USA.ORCID https://orcid.org/0000-0002-8926-5085
Barak RichmanGeorge Washington University Law School, Washington, DC, USA.ORCID https://orcid.org/0000-0001-7172-9956
Arnold MilsteinDepartment of Medicine, Stanford Medical School, Stanford University, Palo Alto, California, USA.ORCID https://orcid.org/0000-0002-2794-2378
Richard KronickFamily Medicine and Public Health, The University of California, San Diego, California, USA.ORCID https://orcid.org/0000-0002-6219-0861

Funding

Arnold VenturesPooled Philanthropic Gifts to Stanford University
6 · The paper itself

Abstract

objectiveTo estimate the extent to which Medicare Advantage (MA) plans underestimate risk, the additional Part A and Part B (A&B) revenue insurers receive as a result, and how this differs across insurers and over time. STUDY SETTING AND

designWe compared projected risk in plan-level bids submitted by insurers to the actual plan-level risk as subsequently reported by the Centers for Medicare and Medicaid Services (CMS). We estimated the additional A&B revenue MA insurers received due to underestimates. DATA SOURCES AND ANALYTICAL SAMPLES: A total of 34,604 MA plans offered by 317 insurers from 2008 to 2020 from MA Bid Data as well as MA enrollment and payment data, all from publicly available CMS sources. PRINCIPAL

findingsFrom 2008 to 2020, the average ratio of actual risk to projected risk was 1.01 (95% Confidence Interval, 1.009-1.011) and plans received additional A&B revenue of $14.6 billion due to risk underestimates. The fraction of plans with a ratio above 1.0 rose from 45% in the smallest enrollment quintile to 62% in the largest enrollment quintile. Among the 10 largest insurers, Blue Cross Blue Shield Highmark underestimated risk by the largest amount, an average of 3% from 2008 to 2020, generating $272 per member per year in additional A&B revenue, followed by Centene (2.1%, $202/member).

conclusionsFrom 2008 to 2020, MA plans systematically underestimated actual risk, reducing benefits for beneficiaries and generating additional A&B revenue of approximately 1% of premiums. The frequency and magnitude of the underestimates increased with plan size. This additional A&B revenue represents a significant fraction of reported MA profit margins, which averaged approximately 3.5% of premiums over the period. CMS should more closely scrutinize the projected risk scores in the annual bids. The Department of Justice should consider whether systematic risk underestimation is a violation of the False Claims Act.

Indexed as

Competitive BiddingInsurance CarriersMedicare Part CCenters for Medicare and Medicaid Services, U.S.HumansMedicare Part BUnited States

Identifiers

PMID42642072
PMCPMC13506252

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.